Chemours Co. Enters Material Definitive Agreement

TL;DR

Chemours signed a big deal on Oct 13th, creating new financial obligations.

AI Summary

On October 13, 2025, The Chemours Company entered into a material definitive agreement. This agreement also created a direct financial obligation for the company. The specific details of the agreement and the financial obligation are not fully disclosed in this filing.

Why It Matters

This filing indicates a significant new agreement for Chemours, which could impact its financial obligations and future business operations.

Risk Assessment

Risk Level: medium — Entering into material definitive agreements and creating new financial obligations can introduce financial and operational risks that are not yet fully understood.

Key Players & Entities

• The Chemours Company (company) — Registrant
• October 13, 2025 (date) — Date of Earliest Event Reported
• Delaware (jurisdiction) — State of Incorporation
• 1007 Market Street Wilmington, Delaware 19801 (address) — Principal executive offices
• (302) 773-1000 (phone_number) — Registrant's telephone number

FAQ

Key Financial Figures

• $0.01 — nge on Which Registered Common Stock ($0.01 par value) CC New York Stock Exchan
• $1,050,000,000 — nded the maturity date of the Company's $1,050,000,000 senior secured U.S. dollar-denominated

Filing Documents

• cc-20251014.htm (8-K) — 59KB
• cc-ex10_1.htm (EX-10.1) — 2172KB
• cc-ex99_1.htm (EX-99.1) — 413KB
• img173633488_0.jpg (GRAPHIC) — 35KB
• 0001193125-25-240643.txt ( ) — 3181KB
• cc-20251014.xsd (EX-101.SCH) — 29KB
• cc-20251014_htm.xml (XML) — 4KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. On October 15, 2025 (the "Amendment No. 4 Effective Date"), The Chemours Company (the "Company") entered into Amendment No. 4 (the "Amendment") by and among the Company, The Chemours Company FC, LLC, the lenders from time to time party thereto and JPMorgan Chase Bank, N.A., as administrative agent (the "Administrative Agent"), which amends the Second Amended and Restated Credit Agreement, dated as of August 18, 2023, among the Company, the lenders from time to time party thereto and the Administrative Agent (as amended, supplemented or otherwise modified from time to time prior to October 15, 2025, the "Existing Credit Agreement" and as amended by the Amendment, the "Credit Agreement"). The Amendment extended the maturity date of the Company's $1,050,000,000 senior secured U.S. dollar-denominated term loan facility (the "Term Loan B-3 US$ Facility") from August 18, 2028 to October 15, 2032. The Amendment changed the applicable margin in respect of the Term Loan B-3 US$ Facility to, at the election of the Company, adjusted Term SOFR + 3.50% or adjusted base rate plus 2.50%. The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Amendment which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference. Item 2.03 Creation of a Direct Financial Obligation or an Obligation under Off-Balance Sheet Arrangement of a Registrant. The information set forth in Item 1.01 is incorporated herein by reference.

01 Other Events

Item 8.01 Other Events. On October 13, 2025 (the "Factor Closing Date"), Chemours Deutschland GmbH, a private company with limited liability incorporated under the laws of Germany, Chemours International Operations Sarl, a private company with limited liability incorporated under the laws of Switzerland, Chemours Netherlands BV, a private company with limited liability incorporated under the laws of Netherlands, Chemours International BV, a private company with limited liability incorporated under the laws of Netherlands, Chemours UK Limited, a private company with limited liability incorporated under the laws of the United Kingdom, and Chemours Belgium BV, a private company with limited liability incorporated under the laws of Belgium (collectively, the "Chemours Sellers"), entered into a Receivables Purchase Agreement (the "Purchase Agreement") with BNP Paribas Factor GmbH ("BNP"). On October 14, 2025, the Company, acceded to joint and several liability for all liabilities of the Chemours Sellers under the Receivables Purchase Agreement. Each of the Chemours Sellers is a direct or indirect wholly-owned subsidiary of the Company. Pursuant to the Purchase Agreement, and subject to the terms and conditions set forth therein, the Chemours Sellers agree to offer for sale and to sell, and BNP agrees to purchase, certain eligible receivables and related rights in an amount of up to an aggregate outstanding balance of 180,000,000. The Purchase Agreement contains customary representations, warranties and covenants. The initial term of the Purchase Agreement extends through October 14, 2026 and will be automatically extended for one-year period, unless earlier terminated in accordance with the terms of the Purchase Agreement. Pursuant to the Purchase Agreement, the purchase price for receivables sold pursuant to the Purchase Agreement will be the nominal amount of such receivables, less customary deductions. The Chemours Sellers and the Company will be obligated to pa

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits (d) Exhibits 10.1 Amendment No. 4, dated as of October 15, 2025, by and among The Chemours Company, The Chemours Company FC, LLC, the Lenders party thereto and JPMorgan Chase Bank, N.A., as Administrative Agent, to the Second Amended and Restated Credit Agreement dated as of August 18, 2023. 99.1* Receivables Purchase Agreement, dated as of October 13, 2025, by and between Chemours Deutschland GmbH, Chemours International Operations Sarl, Chemours Netherlands BV, Chemours International BV, Chemours UK Limited and Chemours Belgium BV and BNP Paribas Factor GmbH. 104 Cover Page Interactive Data File (formatted as Inline XBRL). * Annexes, schedules and/or exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company agrees to furnish supplementally a copy of any omitted attachment to the SEC on a confidential basis upon request.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. THE CHEMOURS COMPANY By: /s/ Shane Hostetter Shane Hostetter Senior Vice President, Chief Financial Officer Date: October 15, 2025

View Full Filing

View this 8-K filing on SEC EDGAR